Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N. Allan(Cornell University), Jennifer R. Brown(Dana-Farber Cancer Institute), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Richard R. Furman(Cornell University), Pietro Taverna, Habte Yimer(Texas Oncology), Gary D Acton(Cancer Research UK), Krish Patel, John M. Pagel(University of Washington), Judith A. Fox(Sunesis (United States)), Mazyar Shadman(University of Washington), Matthew S. Davids(Dana-Farber Cancer Institute), Michael Y. Choi(University of California San Diego), William G. Wierda(University of Maryland, Baltimore), Javier Pinilla‐Ibarz(Moffitt Cancer Center), Daniel L. Combs, Douglas E. Gladstone(Northwell Health), Renee Ward(Sunesis (United States)), Susan O’Brien(University of California, Irvine)
Cited by 37
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k